What Is Ozempic (Semaglutide)?
Ozempic (semaglutide) is a prescription medication used to help manage blood sugar
levels in adults with type 2 diabetes. The drug belongs to a class of medications
known as GLP-1 receptor agonists, which work by helping regulate insulin levels,
reducing appetite, and slowing the movement of food through the stomach.
Ozempic is manufactured by Novo Nordisk and is administered through a weekly
injection. While the medication was originally approved for diabetes management,
it has also become widely discussed due to its weight-loss effects.
Background:
As prescriptions for Ozempic and similar GLP-1 medications increased, reports of
serious gastrointestinal symptoms and other complications have also been reported
by some patients.
Some lawsuits allege that the drug may contribute to conditions such as severe
gastroparesis (commonly referred to as stomach paralysis), intestinal blockages,
persistent vomiting, and other digestive complications. In recent years, additional
legal claims have also examined possible links to certain vision-related conditions.
Research continues to evaluate these potential risks, and findings may vary depending
on the patient’s medical history, dosage, and other factors.
About Ozempic-Related Claims
Ozempic lawsuits generally involve allegations that the manufacturers did not
adequately warn patients and healthcare providers about certain severe side
effects associated with the medication.
Many legal claims focus on whether individuals developed serious gastrointestinal
conditions such as gastroparesis, ileus, or intestinal blockages after using the
drug for diabetes management or weight loss.
Important: We are not a law firm and do not provide legal advice.
We help individuals understand the general claims process, organize intake
information, and (if requested) connect them with independent attorneys
for legal guidance.
The following are common legal allegations discussed in Ozempic-related litigation and are provided for general informational purposes only.
Failure to Warn
Negligence
Product Liability
Potential Health Concerns Alleged in Ozempic Claims
Ozempic litigation commonly focuses on severe gastrointestinal injuries such as
gastroparesis (stomach paralysis), ileus, intestinal blockages, and chronic
vomiting. These conditions can interfere with the normal movement of food
through the digestive system and may require medical treatment or hospitalization.
Some lawsuits also examine possible associations between semaglutide medications
and certain vision-related conditions, including non-arteritic anterior ischemic
optic neuropathy (NAION), a rare condition affecting the optic nerve. Research
regarding these potential risks remains ongoing.
Ozempic Litigation Update
-
Federal Multidistrict Litigation: Many Ozempic and GLP-1 drug cases have been centralized in federal multidistrict litigation (MDL No. 3094) in the Eastern District of Pennsylvania, where courts coordinate pretrial proceedings involving gastrointestinal injury claims.
-
Growing Number of Claims: Thousands of lawsuits have been filed by individuals who allege they experienced serious digestive complications after using GLP-1 medications such as Ozempic, Wegovy, or similar drugs.
-
Ongoing Research and Legal Review: Medical researchers and legal professionals continue to evaluate clinical data, safety reports, and patient experiences related to GLP-1 medications. Litigation and regulatory review are expected to evolve as additional evidence becomes available.
Our Services
Claims We Assist With
